Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial

Background: Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxide, which...

Descrición completa

Detalles Bibliográficos
Main Authors:	Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, M, Kenny, L, Baker, P, Johnstone, E, Khalil, A, von Dadelszen, P, Papageorghiou, A, Alfirevic, Z, Agarwal, U, Willis, E, Mammarella, S, Masson, G, Aquilina, J, Greco, E, Higgins, S, Vinayagam, D, Shaw, L, Stephens, L, Howe, D, Rand, A, Patni, S, Mousa, T, Rabab, A, Russell, H, Hannon, T, Fenn, A, Kilby, M, Selman, T, David, A, Spencer, R, Cohen, K, Breeze, A, McKelvey, A, Impey, L, Loannou, C, Stock, S, Poon, L, Pasupathy, D, Webster, L, Bugg, G
Formato:	Journal article
Publicado:	Elsevier 2017

Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial

Títulos similares